Xoma Royalty News and Activities

Xoma Royalty is a company listed under the stock ticker XOMA (US).

Acquisition, funding and merger involving Xoma Royalty.

• Xoma Royalty and Ligand Pharmaceuticals have announced they will merge  (posted on April 27 2026)..
• Xoma Royalty has acquired Generation Bio (posted on February 11 2026).
• Xoma Royalty has announced the acquisition of Generation Bio  (posted on January 8 2026).
• Xoma Royalty has acquired Mural Oncology (posted on December 8 2025).
• Lava Therapeutics and Xoma Royalty have announced they will merge  (posted on November 24 2025)..
• Xoma Royalty has announced the acquisition of Lava Therapeutics  (posted on October 3 2025).
• Xoma Royalty has announced the acquisition of HilleVax  (posted on August 5 2025).
• ESSA Pharma and Xoma Royalty have announced they will merge  (posted on July 14 2025)..
• See more news about Xoma Royalty Hide news involving Xoma Royalty

View the org chart displaying its 14 main executives

Most searched biographies at Xoma Royalty

• Owen Hughes, Chief Executive Officer
• Heather Franklin, Director
• Barbara Kosacz, Director

Popular executive movements at Xoma Royalty

• Jeffrey Trigilio has joined the company as Chief Financial Officer  (posted on January 12 2026).
• Tom Burns, Senior Vice President, Finance and Chief Financial Officer, has left the company  (posted on January 12 2026).

Create your alert
to follow the executive moves at Xoma Royalty.

Xoma Royalty has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Xoma Royalty

• Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
• XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
• XOMA Royalty Declares Quarterly Preferred Stock Dividends
• XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
• Press Releases
• XOMA Royalty to Present at Investor Conferences in March
• XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
• Company & Portfolio News – XOMA Royalty
• Company & Portfolio News – XOMA Royalty
• XOMA Royalty Announces CFO Transition
• View more press releases Close

Social media about Xoma Royalty

• Xoma Royalty on Wikipedia, Google News & Yahoo Finance
• Xoma Royalty on LinkedIn, X (Twitter) & YouTube